Geno Pharmaceuticals
 
 
Products under ENT
Cetriliv
Betahist / Betahist Forte
Fluner
Cipti/Cipti Forte
Desol
Evica
Snizof
Terbutin
Tricobal - OD
Vertigon Forte
Brupal/Brupal Forte
Fusigen Spray
Cetriliv AC
Vertigon

Cetriliv

 COMPOSITION:

 
Each film coated tablet contains:
Levocetirizine Dihydrochloride 5 mg
 
PHARMACOLOGICAL CLASSIFICATION
Anti allergic
 
 
MODE OF ACTION OF LEVOCETRIZINE (NASAL AREA)
 
Levocetrizine (Cetrilive) H1 receptor, by blocking H1 receptor Cetriliv reduces allergic manifestation
 
PHARMACOKINETICS
Cmax - 27µg/ml            Tmax - .75 hours
½ life - 7 hours             PPB -  94.8%      -       95%
 
 
DISTRIBUTION
The distribution of levocetrizine is restrictive. It is even lower than that usually reported for cetrizine which is lower than that of the other antihistamines of the second generation.
 
Levocetrizine may decrease distribution of the drug into the CNS, resulting in reduced potential for adverse CNS effects.
 
Does not cross blood brain barrier.
 
METABOLISM
Levocetrizine is very poorly metabolized. The cumulative 48 hr excretion as parent compound accounted for 85.8% of the oral dose. No first pass metabolism.
 
EXCRETION 
83.5% drug is excreted through urine and 14.5% is excreted with feces.
 
INDICATION
Seasonal allergic rhinitis, perennial allergic rhinitis
Chronic idiopathic urticaria
Atopic eczema and contact dermatitis
Ocular symptoms
Other indications – reaction to drugs, food and insect bite
Nasal congestion
 
Read More
©2017 Reserved by Geno Pharmaceuticals Pvt. Ltd.
Developed by APJ Systems
Best view at 1024 x 768 resolution